| Clair L Casagrande, APRN, FNP-C | |
|
1111 Trinity Ln, Bloomington, IL 61704-8111 | |
| (309) 663-6461 | |
| Not Available |
| Full Name | Clair L Casagrande |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 1111 Trinity Ln, Bloomington, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578162210 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 209021626 (Illinois) | Secondary |
| 363L00000X | Nurse Practitioner | 209021626 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Advocate Eureka Hospital | Eureka, IL | Hospital |
| Advocate Bromenn Medical Center | Normal, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carle West Physician Group Inc | 8921420308 | 254 |
News Archive
Research released today highlights advances in the use of CRISPR-Cas9 and human induced pluripotent stem cell technologies to identify novel therapeutic targets for neurological disorders such as schizophrenia and addiction.
Machines on cell surfaces, mechanical and lifeless as bed springs, protect blood vessels by responding to blood flow force, according to research published today in the Journal of Cell Biology. By sensing and reacting to force, such machines interfere with inflammatory pathways central to atherosclerosis, the cause of clogged arteries that lead to heart attack and stroke, the authors said. The next set of studies, already underway, seeks to "tweak" the process with the goal of designing a new class of therapies.
Hospital employees recognize and report only one out of seven errors, accidents and other events that harm Medicare patients while they are hospitalized, federal investigators say in a new report.
AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company's innovative bead-based protein analysis platform LUNARIS™.
› Verified 1 days ago
| Entity Name | Carle Eureka Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1184644023 PECOS PAC ID: 3870914393 Enrollment ID: O20200609000028 |
News Archive
Research released today highlights advances in the use of CRISPR-Cas9 and human induced pluripotent stem cell technologies to identify novel therapeutic targets for neurological disorders such as schizophrenia and addiction.
Machines on cell surfaces, mechanical and lifeless as bed springs, protect blood vessels by responding to blood flow force, according to research published today in the Journal of Cell Biology. By sensing and reacting to force, such machines interfere with inflammatory pathways central to atherosclerosis, the cause of clogged arteries that lead to heart attack and stroke, the authors said. The next set of studies, already underway, seeks to "tweak" the process with the goal of designing a new class of therapies.
Hospital employees recognize and report only one out of seven errors, accidents and other events that harm Medicare patients while they are hospitalized, federal investigators say in a new report.
AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company's innovative bead-based protein analysis platform LUNARIS™.
› Verified 1 days ago
| Entity Name | Carle West Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467074138 PECOS PAC ID: 8921420308 Enrollment ID: O20200613000147 |
News Archive
Research released today highlights advances in the use of CRISPR-Cas9 and human induced pluripotent stem cell technologies to identify novel therapeutic targets for neurological disorders such as schizophrenia and addiction.
Machines on cell surfaces, mechanical and lifeless as bed springs, protect blood vessels by responding to blood flow force, according to research published today in the Journal of Cell Biology. By sensing and reacting to force, such machines interfere with inflammatory pathways central to atherosclerosis, the cause of clogged arteries that lead to heart attack and stroke, the authors said. The next set of studies, already underway, seeks to "tweak" the process with the goal of designing a new class of therapies.
Hospital employees recognize and report only one out of seven errors, accidents and other events that harm Medicare patients while they are hospitalized, federal investigators say in a new report.
AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company's innovative bead-based protein analysis platform LUNARIS™.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Clair L Casagrande, APRN, FNP-C 611 W. Park St, Fapc, Urbana, IL 61801 Ph: () - | Clair L Casagrande, APRN, FNP-C 1111 Trinity Ln, Bloomington, IL 61704-8111 Ph: (309) 663-6461 |
News Archive
Research released today highlights advances in the use of CRISPR-Cas9 and human induced pluripotent stem cell technologies to identify novel therapeutic targets for neurological disorders such as schizophrenia and addiction.
Machines on cell surfaces, mechanical and lifeless as bed springs, protect blood vessels by responding to blood flow force, according to research published today in the Journal of Cell Biology. By sensing and reacting to force, such machines interfere with inflammatory pathways central to atherosclerosis, the cause of clogged arteries that lead to heart attack and stroke, the authors said. The next set of studies, already underway, seeks to "tweak" the process with the goal of designing a new class of therapies.
Hospital employees recognize and report only one out of seven errors, accidents and other events that harm Medicare patients while they are hospitalized, federal investigators say in a new report.
AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company's innovative bead-based protein analysis platform LUNARIS™.
› Verified 1 days ago